Somatostatin receptor theranostics: Park and colleagues provide an overview of the current role of SSTR PET in neuroendocrine neoplasms, including selection of patients for peptide-receptor radionuclide therapy, PET-based response assessment, and standardized reporting.
Page 1323
AI in PET image reconstruction: Reader and Schramm consider the methodologies, benefits, and challenges of artificial intelligence applications in PET imaging reconstruction, with a focus on deep learning.
Page 1330
PET/MRI in children with cancer: Baratto and colleagues offer an educational review of clinical applications of integrated 18F-FDG PET/MRI in pediatric oncology, including benefits in patient management and future research potential.
Page 1334
Imaging immune-fibrosis crosstalk: Heo and colleagues discuss key biomarkers upregulated in the immune-fibrosis axis in cardiovascular disease and describe molecular imaging agents with promise in elucidating this pathologic process.
Page 1341
18F-FDOPA PET/CT in small intestine NENs: Imperiale and colleagues look at recent comparative studies on PET/CT tracers in small intestine neuroendocrine neoplasms and argue for a continued role for 18F-FDOPA in this context.
Page 1347
Multimodal glioblastoma imaging: Collet and colleagues look at proliferation, hypervascularization, and hypoxia using multiparametric MRI and PET with 18F-FLT and 18F-FMISO to optimize management and treatment of patients with glioblastoma.
Page 1349
Evolution of sentinel node biopsy: Berger and colleagues review the 30-y technologic development of sentinel lymph node biopsy through a retrospective database of patients with cutaneous melanoma in the head and neck region.
Page 1358
SNB in prostate cancer: Mazzone and colleagues describe the added diagnostic value of sentinel node biopsy for identification of nodal metastases in extended pelvic lymph node dissection, including rates of complications and oncologic outcomes.
Page 1363
PET/CECT in 18F-FDG–avid lymphomas: Marchetti and colleagues assess the added diagnostic contribution of contrast-enhanced CT as compared with unenhanced CT in PET/CT staging and treatment response assessment of 18F-FDG–avid lymphomas.
Page 1372
PET before anti-PD-1 in melanoma: Nakamoto and colleagues determine the prognostic value of 18F-FDG PET/CT parameters in melanoma patients before beginning therapy with antibodies to the programmed cell death–1 receptor.
Page 1380
MUC5AC-targeted PET in pancreatic cancer: Henry and colleagues describe development of RA96, an anti-MUC5AC antibody, and assess its utility in pancreatic cancer diagnosis through immunohistochemical analysis and whole-body PET.
Page 1384
First-in-humans application of 161Tb: Baum and colleagues report on the use of 161Tb-DOTATOC in 2 patients to investigate γ-scintigraphy and SPECT/CT visualization of physiologic and tumor biodistributions to support future development of terbium-based targeted radionuclide therapy.
Page 1391
68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in NETs: Zhu and colleagues evaluate the safety, biodistribution, and dosimetry of these somatostatin receptor–specific antagonists for PET/CT imaging in patients with well-differentiated neuroendocrine tumors..
Page 1398
68Ga-DOTATATE PET for NET therapy response: Ortega and colleagues report on the utility of quantitative parameters from baseline 68Ga-DOTATATE PET/CT and PET performed before the second cycle of peptide receptor radionuclide therapy in predicting response and progression-free survival.
Page 1406
CXCR4 imaging in marginal-zone lymphoma: Duell and colleagues investigate the value of adding CXCR4-directed 68Ga-pentixafor PET/CT to conventional staging in patients with marginal-zone lymphoma.
Page 1415
18F-DCFPyL versus 18F-PSMA-1007: Wondergem and colleagues analyze differences in interreader agreement and detection rates for these regularly used 18F-labeled prostate-specific membrane antigen receptor–targeting radiopharmaceuticals.
Page 1422
PSMA PET after antiandrogen therapy: Zukotynski and colleagues assess changes in uptake on prostate-specific membrane antigen–targeted PET in men with metastatic castration-resistant prostate cancer starting abiraterone or enzalutamide.
Page 1430
RESIST-PC trial: Iravani and Hope offer background and context on the results of a U.S. trial on the efficacy and safety of 177Lu-prostate-specific membrane antigen-617, as presented in 2 articles in this month’s issue of JNM.
Page 1438
RESIST-PC efficacy results: Calais and colleagues report on a prospective multicenter phase 2 study intended to determine the efficacy profiles of 2 activity regimens of 177Lu-prostate-specific membrane antigen therapy in patients with progressive metastatic castrate-resistant prostate cancer.
Page 1440
RESIST-PC safety results: Calais and colleagues detail the safety evaluation of 177Lu-PSMA-617 as derived from a cohort of 64 patients with progressive metastatic castrate-resistant prostate cancer exposed to 177Lu-PSMA-617 in the RESIST-PC trial.
Page 1447
68Ga-NGUL versus 68Ga-PSMA-11: Suh and colleagues compare performances in biodistribution and detection of primary and metastatic lesions for these 2 prostate-specific membrane antigen–targeting tracers in a group of patients with prostate cancer.
Page 1457
Linker design for PSMA hybrid molecules: Eder and colleagues describe a rational linker design aimed at development of a second generation of prostate-specific membrane antigen-11–based hybrid molecules with enhanced pharmacokinetic profiles and improved imaging contrast.
Page 1461
α-RIT for HER2-positive LMGC: Li and colleagues explore in a mouse model whether an α-particle radioimmunotherapy approach with 211At-labeled trastuzumab has efficacy against liver metastasis from primary gastric cancer that is positive for human epidermal growth factor receptor 2.
Page 1468
FRα-selective PET imaging: Guzik and colleagues introduce a folate receptor-α–selective PET agent potentially suitable for identification of patients who might benefit from FRα-targeted therapies.
Page 1475
- © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.